State Street SPDR S&P Health Care Services ETF (XHS) seeks to track the S&P Health Care Services Select Industry Index, which measures the performance of companies providing healthcare services rather than products, including hospitals, managed care organizations, medical facilities, and healthcare technology providers within the U.S. healthcare sector.
How It Works
XHS uses a passively managed, market-capitalization-weighted approach that replicates its benchmark index by holding all constituent stocks in proportion to their market values. The fund focuses specifically on healthcare services companies, excluding pharmaceutical manufacturers, medical device makers, and biotechnology firms. Rebalancing occurs quarterly to maintain alignment with index changes and sector classifications. Holdings typically include 50-80 companies ranging from large hospital chains to specialized healthcare service providers.
Key Features
- Pure-play exposure to healthcare services subsector, excluding pharmaceuticals and medical devices for targeted investment approach
- Captures growing trends in outpatient care, telemedicine, and healthcare technology services within the services segment
- Concentrated portfolio of 50-80 holdings allows meaningful exposure to individual healthcare service providers versus broad sector ETFs
Risks
- This ETF can lose value if healthcare policy changes reduce reimbursement rates or increase regulatory burdens on service providers, potentially causing 15-25% declines
- Sector concentration risk means the fund will underperform during periods when healthcare services lag other market sectors or face industry-specific headwinds
- Individual company risk is elevated due to concentrated holdings, where poor performance from major hospital chains or insurers significantly impacts returns
Who Should Own This
Best suited as a satellite holding (5-15% of portfolio) for investors with 3+ year time horizons seeking targeted healthcare services exposure. Medium-to-high risk tolerance required due to sector concentration and healthcare policy sensitivity. Appropriate for investors wanting to capitalize on aging demographics and healthcare digitization trends without pharmaceutical exposure.